Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approval of Intragastric Balloon System

Device assists adults with weight management

Indications: The ORBERA Intragastric Balloon System is indicated for adult obese patients who have a body mass index (BMI) of 30 to 40 kg/m2 who have been unable to lose weight through diet and exercise.

Mechanism of action: The temporary system is placed into the stomach through the mouth, helps patients lose weight and should be removed after 6 months.

Efficacy and safety: In a clinical trial, 255 patients who used the system lost an average of 22 pounds. The device should not be used in patients who already have an intragastric balloon, have had prior gastrointestinal or bariatric surgery, or have any inflammatory disease of the GI tract.

Citation: FDA website. ORBERA intragastric balloon system. http://www.fda.gov/medicaldevices/productsandmedicalprocedures/deviceapp.... Updated August 6, 2015. Accessed August 11, 2015.

This Week's Must Reads

Healthy Lifestyle Impact on Life Expectancies, Circulation; ePub 2018 Apr 30; Li, Pan, et al

Preventability of Early vs Late Readmissions, Ann Intern Med; ePub 2018 May 1; Graham, et al

Risk of T2D Among Lesbian and Bisexual Women, Diabetes Care; ePub 2018 May 2; Corliss, et al

Breast Biopsy Rates Following BC Screening, JAMA Intern Med; 2018 Apr; Buist, et al

Diet Quality Among Non-Hispanic Blacks, Am J Clin Nutrit; 2018 May 2; Brown, et al

Must Reads in Obesity

Sleep Insufficiency’s Role in Childhood Obesity, Sleep Medicine; ePub 2018 Apr 5; Arora, et al

Impact of Intensive Weight Loss & Life Expectancy, Diabetes Care; ePub 2018 Mar 15; Gregg, et al

Obesity Progression and Incident Diabetes, Diabetes Care; ePub 2018 Mar 5; Stokes, et al

Association of BMI with Lifetime Risk of CVD, JAMA Cardiol; ePub 2018 Feb 28; Khan, et al

Effect of Low-Fat vs Low-Carb Diet on Weight Loss, JAMA; 2018 Feb 20; Gardner, et al